A European regulatory panel voted against approval of Biogen Alzheimer's disease drug, dealing a possible blow to the prospects of the drug already grappling with a slow rollout in the United States. Fred Katayama reports.
00:34
02:13
01:16
00:59
01:41
01:17
02:15
01:48
00:33
01:22
01:53
01:05
00:40
02:08
01:14
01:15
01:33
01:30
00:25
01:02
01:02
01:05
01:14
00:50
01:15
02:02
01:02
01:06
01:42
02:43
01:08
01:25
01:57
01:57
01:37
01:50
00:49
02:32
01:30
02:02
02:13
02:00
01:01
01:11
01:03
01:01
01:02
02:11
01:14
01:01
01:24
01:08
00:20
00:50
01:44
00:46
01:47
00:14
01:53
00:36
01:51
01:26
01:33
02:03
01:02
01:57
00:29
01:28
01:21
00:40
01:17
01:48
01:53
01:09
03:40
01:13
01:55
01:39
02:01
03:38
02:05
01:20
01:03
01:16
01:50
00:53
03:21
01:33
01:21
01:22
02:18
01:16
01:42
01:25
01:27
02:27
02:27
01:30
01:51
01:43